Free press releases distribution network?

Agency / Source: GTCbio - Biopharmaceutical Conference

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Amy Scott-Billman VP at GlaxoSmithKline to Give Keynote at Modern Drug Discovery & Development Summit - Amy M. Scott-Billman, Vice President of Global Regulatory Strategy for Immunotherapeutics at GlaxoSmithKline Biologicals, to do Keynote Presentation at GTCbio’s 5th Modern Drug Discovery & Development Summit on October 14-16, 2009 in San Diego, CA
Amy Scott-Billman VP at GlaxoSmithKline to Give Keynote at Modern Drug Discovery & Development Summit

 

PRZOOM - /newswire/ - Monrovia, CA, United States, 2009/07/29 - Amy M. Scott-Billman, Vice President of Global Regulatory Strategy for Immunotherapeutics at GlaxoSmithKline Biologicals, to do Keynote Presentation at GTCbio’s 5th Modern Drug Discovery & Development Summit on October 14-16, 2009 in San Diego, CA.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Amy Scott-Billman, Vice President of Global Regulatory Strategy for Immunotherapeutics at GlaxoSmithKline Biologicals, is to give a keynote presentation concerning regulatory considerations & challenges for immunotherapeutic/diagnostic co-development at GTCbio’s 5th Modern Drug Discovery & Development Summit, on October 14th-16th, 2009, in San Diego, CA.

Amy’s presentation highlights GSK's approach to immunotherapy for cancer (Antigen-Specific Cancer Immunotherapeutics), challenges of co-development - biologic & companion in vitro diagnostics (screening assays & biomarkers), development/regulatory challenges/considerations for the biologic component, and development/regulatory challenges/considerations for the in vitro diagnostic component.

Amy is the Vice President of Global Regulatory Strategy for Immunotherapeutics at GlaxoSmithKline Biologicals (GSK Bio) where she manages a global staff responsible for all regulatory activities relevant to the development and commercialization of immunotherapeutic products for cancer and chronic disorder indications. Amy is also responsible for the regulatory aspects of in-licensing opportunities and for partnerships with external parties for the global development of companion in vitro diagnostics.

Prior to joining regulatory affairs at GSK in 1998, Amy served in GSK’s World Wide Supply Operations as a Director of Quality Assurance & Compliance; supporting various business units including Research & Development, Biopharmaceuticals and Pharmaceuticals. Before joining GSK, Amy served for nearly 9 years at the Center for Biologics Evaluation and Research (CBER) at the US FDA in several capacities, including senior management, reviewer and inspector of biopharmaceutical manufacturing facilities. Amy received her B.S. in Microbiology from Pennsylvania State University and her M.S. in Biotechnology from Johns Hopkins University.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: GTCbio - Biopharmaceutical Conference

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Amy Scott-Billman VP at GlaxoSmithKline to Give Keynote at Modern Drug Discovery & Development Summit

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Josette Barba 
626-256-6405 infogtcbio[.]gtcbio.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any GTCbio - Biopharmaceutical Conference securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From GTCbio - Biopharmaceutical Conference / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
Sugar Element of Keratan Sulfate Halts the Progress of Emphysema Finds RIKEN
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
MDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China
Pulse Certified As A Level Four Multichannel Content Agency by Veeva Systems
BD Launches Advanced Prefillable Syringe for Higher Volume Injection of Biologics

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  1Click Games

Visit  BizJobs.com







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today